Pembrolizumab for kids with liver cancer that came back
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies pembrolizumab (an immune therapy) in children and young people with hepatocellular carcinoma (HCC) that has returned or did not respond to earlier treatment. The goal is to see whether it can shrink tumors and help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 30 years old when you enroll.
- Your liver cancer is confirmed by biopsy (or it can be a related category called HCN NOS), and it has come back or is not responding to treatment.
- Your doctor can measure at least one tumor spot on scans or exam (a “measurable” lesion).
- Your general activity level is good enough: Karnofsky score ≥60 if age 16 or older, or Lansky score ≥60 if under 16.
- You must have enough bone marrow and organ function (blood counts, liver tests, kidney tests, and thyroid tests) and you must have fully recovered from side effects of any past cancer treatment.
- You must not have had pembrolizumab or any other immune “checkpoint” drugs before, and you must not be on certain medicines (like chronic steroids or other investigational drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
This trial tests a combination of immunotherapy drugs given directly into the liver’s blood supply as a first treatment for liver cancer. It aims to see if this approach can shrink tumors and improve outcomes for people with relatively preserved liver function.
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
This trial tests a combination of an immunotherapy (pucotenlimab), a targeted therapy (lenvatinib), and chemotherapy for children with advanced or relapsed hepatoblastoma that hasn't responded to prior treatment. The goal is to see if this combination can help shrink or control the tumor.
This trial tests a new drug that combines two immunotherapy approaches (PD-1 and IL-2) given before surgery to treat hepatocellular carcinoma (liver cancer) that has come back 3 months to 2 years after your first surgery. The goal is to shrink the tumor and help your body's immune system fight the cancer.
Hear when a new Fibrolamellar Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.